HT-29 Transfection Reagent

Catalog # 1771 - 0.5 mL        $ 85.00 Catalog # 1772 - 1.5 mL        $ 201.00 Transfection reagent for HT-29 cells Kit includes Transfection Enhancer reagent and recommended transfection protocols Protocols provided for transfection of mRNA, siRNA and microRNA High transfection efficiency for human colorectal adenocarcinoma cells Compatible with transfection in any plate format Reproducible transfection Optimized transfection protocols are adapted for use with both standard & reverse transfection methods Developed and manufactured by Altogen Biosystems Transfection Efficiency: Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by Fluorescent microscopy. Transfection Protocol: Transfection protocols are provided with the purchase of the reagent.

Transfection Resource

Visit Altogen Biosystems Transfection Resource: RNAi applications (siRNA transfection, microRNA transfection, plasmid DNA transfection), stable and transient DNA transfection, delivery methods, electroporation, microinjection, dendrimer-based, non-viral and virus-mediated gene delivery, liposome and non-liposomal reagents. Transfection of cancer cell lines vs primary cultures. RNA Interference as a research tool for gene expression studies, gene silencing in neuronal cells, RNAi therapeutics and In Vivo Transfection Reagents from Altogen Biosystems.

Primary cell cultures are used in biological and gene therapy studies and serve as important model systems that may more accurately represent the biology of normal cells. Many cultured cell lines, as well as the majority of primary cell cultures are able to be transfected with exogenous nucleic acids when appropriate transfection approaches are employed. Since the majority of transfection methods causes significant toxicity in primary cell cultures, optimizing this procedure, specifically the protocol and reagents to be utilized, is essential for developing an effective transfection strategies for a given cell type. ALTOGEN® Kits for primary cells and sensitive cell lines have been designed to have significantly lower cytotoxicity than classical alternatives.

HT-29 (human colorectal adenocarcinoma cells)

HT-29 was derived in 1964 from the tumor of a 44-year-old Caucasian woman with colon adenocarcinoma in 1964. HT29 cells are human intestinal epithelial cells which produce the secretory component of Immunoglobulin A (IgA) and carcinoembryonic antigen (CEA). The HT-29 line is designated heterotransplantable, forming well-differentiated grade I tumors. The structure of HT-29 cells include microvilli, microfilaments, mitochondria, smooth and rough endoplasmic reticulum with free ribosomes, lipid droplets, limited primary lysosomes and many secondary lysosomes. The cells express urokinase receptors, but do not have detectable plasminogen activator activity. HT-29 cells have been shown to be negative for CD4, but there is expression of galactose ceramide. HT-29 cells are used for tumourigenicity studies. The line is considered a useful model system to study epithelial differentiation in vitro.

Transfection Resource

siRNA Transfection || Transfection Methods || RNAi || siRNA Library Screening || RNAi Therapeutics || Cell Line Specific Transfection Reagents

Featured Products

In Vivo Transfection Reagents || HepG2 Transfection Reagent || CHO Reagent || MDA-MB Transfection Reagent || Cos7 Transfection Reagent || PC-12 Reagent

Altogen Research Services

Altogen Custom Services provide specialized biotechnology and pharmaceutical services, including generation of stable cell lines, RNA Interference (RNAi) services, in vivo studies, assay development, screening and transfection services. Altogen Services offers complete set of pre-clinical research studies.